Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Based on results of phase 2 and 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received either 1 or ≥2 previous line of therapy, as well as salvage autologous stem-cell transplantation.

Source:

The Lancet Oncology